DMG Blockchain Solutions: Leading the Way to Compliance and Innovation with SOC 2 Type II Certification and Hydro Miner Acquisition

DMG Blockchain Solutions Achieves SOC 2 Type II Compliance Enhancing Security and Regulatory Compliance VANCOUVER, British Columbia, Nov. 11, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a leading vertically integrated blockchain and data center technology company, announces that it has achieved SOC 2 Type II compliance…

Read More

Exciting Progress in Cancer Treatment: Citius Pharmaceuticals and Citius Oncology Report Positive Findings from Phase I Clinical Trial of Pembrolizumab and Lymphir for Recurrent Solid Tumors

Citius Pharmaceuticals Announces Promising Results in Phase I Clinical Trial for Gynecological Malignant Tumors CRANFORD, N.J. , Nov. 11, 2024 /PRNewswire/ Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objective Response Rate (ORR) 33% Clinical Benefit…

Read More

Diamond Estates Wines & Spirits Announces Further Replacement of Previously Issued Convertible Debentures

Diamond Estates Announces Replacement of Convertible Debentures Overview Niagara-on-the-Lake, Ontario–(Newsfile Corp. – November 11, 2024) – Diamond Estates Wines & Spirits Inc. (TSXV: DWS) (“Diamond Estates” or the “Company”) has announced the replacement of $4.759 million aggregate principal amount of 10.0% unsecured convertible debentures of the Company. This includes debentures issued to Lassonde Holding and…

Read More

Innovative Bispecific Antibody ALGAPV-527 Meets Key Trial Endpoints in Phase 1 Solid Tumor Study

Aptevo Therapeutics and Alligator Bioscience Report Favorable Safety and Efficacy Data for ALG.APV-527 Positive Results in Phase 1 Trial Aptevo Therapeutics and Alligator Bioscience have announced encouraging preliminary data from their Phase 1 trial of ALG.APV-527, a novel bispecific antibody designed for the treatment of solid tumors expressing tumor antigen 5T4. The data presented at…

Read More

Jana Gerber, Schneider Electric’s Microgrid President, Earns Prestigious Gold Stevie Award for Empowering Customers to Save Energy

Gerber Receives Gold Stevie Award for Sustainability Jana Gerber, North American President of Microgrids for Schneider Electric, has been honored with a prestigious Gold Stevie Award in the Saving Energy, Sustainability Category. The Stevie Awards for Women in Business, which received over 1,500 entries this year, recognizes the outstanding achievements of women in leadership roles…

Read More

Lantheus Continues to Support CMS CY25 Rule for Improved Payment of Specialized Diagnostic Radiopharmaceuticals and Reaffirms PYLARIFY’s Projected Success in 2025

Lantheus Holdings, Inc. Notes Updated Payment Rates for PYLARIFY in 2025 Medicare OPPS Final Rule Introduction On November 11, 2024, Lantheus Holdings, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) have posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective…

Read More

Hey there, readers! Assertio’s Got Something to Say About That Short-Seller Letter

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial…

Read More